### Financial Performance Metrics
- Revenue: $5.26 million (QoQ increase of 235.8%, YoY decrease of 52.71%)
- Gross Profit: $4.61 million, showcasing a gross profit margin improvement (QoQ increase of 236.2%)
- Operating Income: -$43.87 million (indicating increased operational costs despite revenue growth)
- Net Income: -$37.72 million (reflective of a continued strain)
- EPS: -$0.69, an improvement in quarterly loss per share vs. previous periods.
### Balance Sheet Observations
- Cash Reserves: $253.78 million, coupled with short-term investments of $123.20 million, solidifying liquidity needs to support ongoing operations.
- Total Liabilities: $588.89 million, with total stockholders’ equity at -$4 million, revealing a challenging capital structure primarily driven by sustained losses.
Management has reiterated future growth potential despite current losses, relying on pending approvals for clinical products.